Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.

Thomas Neumann, Laila Schneidewind, Thomas Thiele, Meike Schulze, Anne F Klenner, Christoph Busemann, Daniel Pink, Andreas Greinacher, Gottfried Dölken, William H Krüger,

Journal of cancer research and clinical oncology, January 18, 2016

In patients undergoing allogeneic stem cell transplantation, conditioning regimens containing alemtuzumab instead of anti-thymocyte globulin (ATG) may result in an earlier platelet engraftment and a reduced number of platelet transfusions. We performed a retrospective, single-center, case-control study analyzing time to engraftment and transfusion needs using alemtuzumab in comparison with ATG as part of conditioning protocol. Median values for time to platelet engraftment, number of transfused platelet concentrates and number of transfused red cell concentrates were 12 versus 19.5 days (p 

Pubmed Link: 26779644